Page last updated: 2024-09-02

ecteinascidin 743 and Endometrial Neoplasms

ecteinascidin 743 has been researched along with Endometrial Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baresic, T; Buonadonna, A; Canzonieri, V; Corona, G; Lara, DP; Miolo, G; Santeufemia, DA; Viel, A	1
Kim, HJ; Kim, JW; Kim, M; Lee, KH; Suh, DH	1
Bayever, E; Braly, P; Crispens, M; Doering, D; Lisyanskaya, A; Markman, M; McMeekin, DS; Michiels, B; Oza, AM	1

Reviews

1 review(s) available for ecteinascidin 743 and Endometrial Neoplasms

Article	Year
Major clinical research advances in gynecologic cancer in 2015. Journal of gynecologic oncology, 2016, Volume: 27, Issue:6 Topics: Biomedical Research; Breast Neoplasms; Combined Modality Therapy; Dioxoles; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Papillomavirus Vaccines; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Uterine Cervical Neoplasms; Uterine Neoplasms	2016

Article

Year

Major clinical research advances in gynecologic cancer in 2015.

Journal of gynecologic oncology, 2016, Volume: 27, Issue:6

Topics: Biomedical Research; Breast Neoplasms; Combined Modality Therapy; Dioxoles; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Papillomavirus Vaccines; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Uterine Cervical Neoplasms; Uterine Neoplasms

2016

Trials

1 trial(s) available for ecteinascidin 743 and Endometrial Neoplasms

Article	Year
Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. Gynecologic oncology, 2009, Volume: 114, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Tetrahydroisoquinolines; Trabectedin; Young Adult	2009

Article

Year

Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

Gynecologic oncology, 2009, Volume: 114, Issue:2

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Tetrahydroisoquinolines; Trabectedin; Young Adult

2009

Other Studies

1 other study(ies) available for ecteinascidin 743 and Endometrial Neoplasms

Article	Year
Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma. Cancer biology & therapy, 2016, 10-02, Volume: 17, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Neoplasms; BRCA2 Protein; Dioxoles; Endometrial Neoplasms; Epirubicin; Female; Genes, BRCA2; Germ-Line Mutation; Humans; Ifosfamide; Liver Neoplasms; Middle Aged; Mutation, Missense; Sarcoma, Endometrial Stromal; Tetrahydroisoquinolines; Trabectedin	2016

Article

Year

Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.

Cancer biology & therapy, 2016, 10-02, Volume: 17, Issue:10

Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Neoplasms; BRCA2 Protein; Dioxoles; Endometrial Neoplasms; Epirubicin; Female; Genes, BRCA2; Germ-Line Mutation; Humans; Ifosfamide; Liver Neoplasms; Middle Aged; Mutation, Missense; Sarcoma, Endometrial Stromal; Tetrahydroisoquinolines; Trabectedin

2016